Opinion

Video

Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.

  1. What are the current guidelines for testing for targetable mutations in breast cancer, and how widely are they followed in clinical practice? How can biomarker testing for targetable mutations, such as PIK3CA or AKT1, be improved or streamlined?
    1. How accessible are these biomarker tests in community oncology? 
  2. How is personalized medicine expected to impact the future use of targeted therapies (such as the PI3K pathway inhibitors) in breast cancer? What developments are needed to fully realize its potential?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo